GF Fund Management CO. LTD. bought a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 97,924 shares of the company's stock, valued at approximately $7,656,000.
Several other institutional investors and hedge funds have also recently modified their holdings of GEHC. CoreFirst Bank & Trust purchased a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $25,000. Runnymede Capital Advisors Inc. purchased a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $28,000. LGT Financial Advisors LLC raised its holdings in shares of GE HealthCare Technologies by 46.2% in the 4th quarter. LGT Financial Advisors LLC now owns 389 shares of the company's stock valued at $30,000 after acquiring an additional 123 shares in the last quarter. Accredited Wealth Management LLC purchased a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $30,000. Finally, Bank of Jackson Hole Trust purchased a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 82.06% of the company's stock.
GE HealthCare Technologies Trading Down 0.1%
GE HealthCare Technologies stock traded down $0.06 during trading hours on Thursday, reaching $71.10. The company had a trading volume of 1,157,556 shares, compared to its average volume of 3,438,455. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The company has a 50-day moving average price of $69.41 and a 200 day moving average price of $79.29. The firm has a market cap of $32.55 billion, a price-to-earnings ratio of 16.46, a P/E/G ratio of 3.19 and a beta of 1.21. GE HealthCare Technologies Inc. has a 12-month low of $57.65 and a 12-month high of $94.80.
GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.91 by $0.10. The business had revenue of $4.78 billion for the quarter, compared to analysts' expectations of $4.66 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The business's quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.90 EPS. Equities analysts forecast that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.
GE HealthCare Technologies declared that its board has authorized a stock buyback program on Wednesday, April 30th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to buy up to 3.1% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued.
GE HealthCare Technologies Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Thursday, May 15th. Investors of record on Friday, April 25th were given a dividend of $0.035 per share. The ex-dividend date was Friday, April 25th. This represents a $0.14 annualized dividend and a dividend yield of 0.20%. GE HealthCare Technologies's dividend payout ratio is presently 2.95%.
Analyst Upgrades and Downgrades
GEHC has been the topic of a number of research reports. BTIG Research set a $95.00 price objective on GE HealthCare Technologies and gave the company a "buy" rating in a report on Monday, April 14th. Citigroup decreased their price objective on GE HealthCare Technologies from $105.00 to $86.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. UBS Group raised GE HealthCare Technologies from a "sell" rating to a "neutral" rating and decreased their price objective for the company from $74.00 to $73.00 in a report on Monday, May 5th. Piper Sandler decreased their price objective on GE HealthCare Technologies from $104.00 to $88.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Finally, Wells Fargo & Company decreased their price objective on GE HealthCare Technologies from $103.00 to $89.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of "Moderate Buy" and a consensus target price of $88.27.
Check Out Our Latest Analysis on GE HealthCare Technologies
About GE HealthCare Technologies
(
Free Report)
GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.
Further Reading
Before you consider GE HealthCare Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GE HealthCare Technologies wasn't on the list.
While GE HealthCare Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
